Latest News
Conference Coverage
Empagliflozin’s heart failure benefits linked to volume drop
ANAHEIM, CALIF. – About half of the observed benefit was tied to a rise in average hematocrit level.
From the Journals
Vasopressin stimulates red blood cell production
The findings could have implications for the development of new treatments designed to stimulate RBC production after bleeding, chemotherapy, or...
From the Journals
Defining quality in lung cancer surgery
Quality initiatives can lead to better outcomes, but can be complex.
From the Journals
Real-world data support extended cervical cancer screening interval
The study examines several rounds of cotesting with the high-risk HPV test and cytology.
From the Journals
Researchers identify potential gene target for AML drug development
Study pinpoints a new mechanism of gene regulation in acute myeloid leukemia.
Conference Coverage
SABCS opening plenary to address potential of RT to transform tumors into vaccines
Dr. Silvia Formenti of Weill Cornell Medicine will outline her ongoing clinical work to combine RT with immune checkpoint inhibitors to evoke T-...
Feature
Marketplace confusion opens door to questions about skinny plans
Such plans, sold for the first time to individuals, come amid uncertainty over the fate of the ACA.
From the Journals
Novel therapies may expand anti-MZL toolbox
Treatment successes in other hematologic malignancies offer promise for MZL.
From the Journals
Rare epidermotropic MZL yields to rituximab
A case of epidermotropic MZL in an otherwise healthy 69-year-old man shows the efficacy of rituximab.
From the Journals
Upfront chemotherapy yields excellent survival in patients with MZLs
The study assessed FND-R or CHOP-R as upfront chemotherapy regimens in patients with either extranodal, nodal, or splenic MZL.
Conference Coverage
Marginal zone lymphoma treatment studies to be presented at ASH
Several studies will focus on combination treatment approaches in MZL.